First Time Loading...
N

NewAmsterdam Pharma Company NV
NASDAQ:NAMS

Watchlist Manager
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Watchlist
Price: 19.68 USD 1.97% Market Closed
Updated: Jun 11, 2024
Section:
 

Wall Street
Price Targets

NAMS Price Targets Summary
NewAmsterdam Pharma Company NV

Wall Street analysts forecast NAMS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NAMS is 35.41 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.

NAMS Lowest Forecast
Wall Street Target
28.28 USD
44% Upside
NAMS Average Forecast
Wall Street Target
35.41 USD
80% Upside
NAMS Highest Forecast
Wall Street Target
47.25 USD
140% Upside
Lowest
Price Target
28.28 USD
44% Upside
Average
Price Target
35.41 USD
80% Upside
Highest
Price Target
47.25 USD
140% Upside
NewAmsterdam Pharma Company NV Competitors:
Price Targets
SPRO
Spero Therapeutics Inc
435% Upside
LYEL
Lyell Immunopharma Inc
174% Upside
603387
Getein Biotech Inc
338% Upside
NGNE
Neurogene Inc
27% Upside
SPRO
Spero Therapeutics Inc
435% Upside
LYEL
Lyell Immunopharma Inc
174% Upside
603387
Getein Biotech Inc
338% Upside
NGNE
Neurogene Inc
27% Upside
BIO
Biotest AG
18% Downside
OCC
Orthocell Ltd
56% Upside
LEGN
Legend Biotech Corp
87% Upside
BNTX
BioNTech SE
19% Upside

Revenue
Forecast

Revenue Estimate
NewAmsterdam Pharma Company NV

The compound annual growth rate of NewAmsterdam Pharma Company NV's revenue for the next 4 years is -36%.

N/A
Past Growth
-36%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
NewAmsterdam Pharma Company NV

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
NewAmsterdam Pharma Company NV

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
NAMS intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAMS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAMS stock valuation using valuation multiples.
Wall Street Estimates
NAMS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAMS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NAMS's stock price target?
Price Target
35.41 USD

According to Wall Street analysts, the average 1-year price target for NAMS is 35.41 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.

What is NewAmsterdam Pharma Company NV's Revenue forecast?
Projected CAGR
-36%

The compound annual growth rate of NewAmsterdam Pharma Company NV's revenue for the next 4 years is -36%.

ALPHA SPREAD
Join more than 146,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.